BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Jiang, Ben yuan ^a,b   Zhang, Xu chao ^a   Su, Jian ^a   Meng, Wei ^a   Yang, Xue ning ^a   Yang, Jin ji ^a   Zhou, Qing ^a   Chen, Zhi yong ^a   Chen, Zhi hong ^a   Xie, Zhi ^a   Chen, Shi liang ^a   Wu, Yi long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

BCL11A; microRNA; Non small cell lung cancer; Prognosis; Proto oncogene

Indexed keywords

MICRORNA; MICRORNA 30A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL DIFFERENTIATION; CELL MATURATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE; MALE; PROTO ONCOGENE; PROTO ONCOGENE B CELL LYMPHOMA 11A; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; SQUAMOUS CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; RECURRENCE; RNA, MESSENGER;

EID: 84878817419     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-61     Document Type: Article

References (34)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008, 359:1367-1380. 10.1056/NEJMra0802714, 18815398.
2. Wu YL, Zhou Q. Clinical trials and biomarker research on lung cancer in China. Expert Opin Ther Targets 2012, 16(Suppl 1):S45-S50.
3. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:3316-3321. 10.1200/JCO.2010.33.3757, 21788562.
4. Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS, Song LB. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer 2009, 115:1507-1517. 10.1002/cncr.24128, 19170237.
5. Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Canc Res 2011, 17:3706-3715.
6. Liu P, Keller JR, Ortiz M, Tessarollo L, Rachel RA, Nakamura T, Jenkins NA, Copeland NG. Bcl11a is essential for normal lymphoid development. Nat Immunol 2003, 4:525-532. 10.1038/ni925, 12717432.
7. Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine M, Bender MA, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009, 460:1093-1097. 10.1038/nature08243, 19657335.
8. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002, 99:1474-1477. 10.1182/blood.V99.4.1474, 11830502.
9. Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL, Liu H, Price HP, Gesk S, Steinemann D, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 2001, 98:3413-3420. 10.1182/blood.V98.12.3413, 11719382.
10. Avram D, Fields A, Senawong T, Topark-Ngarm A, Leid M. COUP-TF (chicken ovalbumin upstream promoter transcription factor)-interacting protein 1 (CTIP1) is a sequence-specific DNA binding protein. Biochem J 2002, 368:555-563. 10.1042/BJ20020496, 1223006, 12196208.
11. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008, 134:521-533. 10.1016/j.cell.2008.07.020, 2586071, 18692474.
12. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495-500. 10.1038/ng1536, 15806104.
13. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798. 10.1016/S0092-8674(03)01018-3, 14697198.
14. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG. miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res 2007, 35:D149-D155. 10.1093/nar/gkl904, 1669779, 17108354.
15. Chen Z, Luo HY, Steinberg MH, Chui DH. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 2009, 42:144-149. 10.1016/j.bcmd.2008.12.003, 19153051.
16. Kuo TY, Hsueh YP. Expression of zinc finger transcription factor Bcl11A/Evi9/CTIP1 in rat brain. J Neurosci Res 2007, 85:1628-1636. 10.1002/jnr.21300, 17455301.
17. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842. 10.1126/science.1165409, 19056937.
18. Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, Pulford K, Banham AH, Stockwin L, Shaffer AL, et al. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Canc 2006, 5:18.
19. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Canc 2005, 114:683-695.
20. Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood 2009, 113:1075-1085. 2635073, 18948576.
21. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075. 10.1038/nature07423, 2694412, 18948947.
22. Yu Y, Wang J, Khaled W, Burke S, Li P, Chen X, Yang W, Jenkins NA, Copeland NG, Zhang S, Liu P. Bcl11a is essential for lymphoid development and negatively regulates p53. J Exp Med 2012, 209:2467-2483. 10.1084/jem.20121846, 3526365, 23230003.
23. Pulford K, Banham AH, Lyne L, Jones M, Ippolito GC, Liu H, Tucker PW, Roncador G, Lucas E, Ashe S, et al. The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. Leukemia 2006, 20:1439-1441. 10.1038/sj.leu.2404260, 16710303.
24. Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W, Postma DS, Groen HJ, van den Berg A. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Canc 2009, 66:372-378.
25. Kamimura K, Ohi H, Kubota T, Okazuka K, Yoshikai Y, Wakabayashi Y, Aoyagi Y, Mishima Y, Kominami R. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun 2007, 355:538-542. 10.1016/j.bbrc.2007.02.003, 17306224.
26. Kamimura K, Mishima Y, Obata M, Endo T, Aoyagi Y, Kominami R. Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages. Oncogene 2007, 26:5840-5850. 10.1038/sj.onc.1210388, 17369851.
27. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Canc Res 2010, 16:376-383.
28. Insinga A, Cicalese A, Faretta M, Gallo B, Albano L, Ronzoni S, Furia L, Viale A, Pelicci PG. DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. Proc Natl Acad Sci USA 2013, 110:3931-3936. 10.1073/pnas.1213394110, 23417300.
29. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7:759-764. 10.4161/cc.7.6.5834, 18344688.
30. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9:102-114.
31. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 2009, 7:25. 10.1186/1479-5876-7-25, 2672079, 19366452.
32. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699. 10.1126/science.1165395, 2684823, 19008416.
33. Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011, 117:3945-3953. 10.1182/blood-2010-11-316893, 3087525, 21321359.
34. Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R. MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Canc Res 2009, 69:5639-5642.